We are live on ! Find out more

Liquidia Corp

LQDA

Market cap $4.03B

44.99 USD

-0.73

1.6%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

44.02

-0.97

2.16%

1 day

-1.6%

5 days

12.87%

1 month

-36.36%

3 months

-48.18%

6 months

17.93%

Year to date

43.28%

1 year

100.4%

5 years

1,099.73%

10 years

305.32%

About: Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Employees: 216

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 46.8%

Neutral 44.7%

Negative 8.5%

Zacks Investment Research

Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?

LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.

Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?

Zacks Investment Research

Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?

Liquidia Corporation (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?

Liquidia Corporation Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money on Your LQDA Investments

New York, New York--(Newsfile Corp. - October 21, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Happened?

Liquidia Corporation Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money on Your LQDA Investments

Zacks Investment Research

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Proactive Investors

Liquidia shares surge 25% as settlement ends United Therapeutics litigation

Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia's inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.

Liquidia shares surge 25% as settlement ends United Therapeutics litigation

24/7 Wall Street

United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%

A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.

United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%

This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.

Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.

This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.

Investors Business Daily

Liquidia And United Therapeutics Settle; But Only One Stock Skyrocketed

Liquidia stock skyrocketed Wednesday on settlement deal with United Therapeutics that allows its drug to stay on the market.

Liquidia And United Therapeutics Settle; But Only One Stock Skyrocketed

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it has entered into a global settlement agreement with United Therapeutics Corporation (Nasdaq: UTHR) that resolves all pending litigation between the companies. Importantly, YUTREPIA® (treprostinil) inhalation powder will remain available to patients with PAH without disruption.

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky

Liquidia shareholders took a roughly 57% loss after a court found that Yutrepia infringed two valid United Therapeutics patent claims. The investigation concerns whether investors had an accurate picture of that litigation risk before the losses occurred.

Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky

See News Rankings

Price charts implemented using Lightweight Charts™